Attention Deficit Hyperactivity Disorder (ADHD) Treatments
Find Attention Deficit Hyperactivity Disorder (ADHD) Treatments
Medications for Attention Deficit Hyperactivity Disorder (ADHD)
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Attention Deficit Hyperactivity Disorder (ADHD).
Found 6 Approved Drugs for Attention Deficit Hyperactivity Disorder (ADHD)
methYLphenidate
Brand Names
Concerta, Cotempla, Daytrana, Jornay, Metadate, Methylin, methYLphenidate Transdermal, QuilliChew, Quillivant, Relexxii, Ritalin
methYLphenidate
Brand Names
Concerta, Cotempla, Daytrana, Jornay, Metadate, Methylin, methYLphenidate Transdermal, QuilliChew, Quillivant, Relexxii, Ritalin
Form: Patch, Tablet, Suspension, Capsule, Solution
Method of administration: Oral, Transdermal
FDA approval date: December 31, 1955
Classification: Central Nervous System Stimulant
CONCERTA is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65. CONCERTA is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65. ( 1 )
Intuniv
Generic Name
Guanfacine
Intuniv
Generic Name
Guanfacine
Form: Tablet
Method of administration: Oral
FDA approval date: October 17, 1995
Classification: Central alpha-2 Adrenergic Agonist
INTUNIV ® is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications. INTUNIV ® is a central alpha 2A -adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications ( 1, 14 ).
Lisdexamfetamine Dimesylate
Brand Names
Arynta, Vyvanse
Lisdexamfetamine Dimesylate
Brand Names
Arynta, Vyvanse
Form: Tablet, Capsule, Solution
Method of administration: Oral
FDA approval date: February 23, 2007
Classification: Central Nervous System Stimulant
ARYNTA is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies ( 1.
Clonidine
Brand Names
Catapres-TTS-1, Catapres-TTS-2, Catapres-TTS-3, Clonidine HCI, Clonidine Transdermal, Duraclon, Javadin, Nexiclon, ONYDA, Qlonilik
Clonidine
Brand Names
Catapres-TTS-1, Catapres-TTS-2, Catapres-TTS-3, Clonidine HCI, Clonidine Transdermal, Duraclon, Javadin, Nexiclon, ONYDA, Qlonilik
Form: Patch, Injection, Tablet, Suspension, Solution
Method of administration: Epidural, Oral, Intravenous, Transdermal
FDA approval date: September 04, 1987
Classification: Central alpha-2 Adrenergic Agonist
Catapres‑TTS ® is indicated in the treatment of hypertension. It may be employed alone or concomitantly with other antihypertensive agents.
Dexmethylphenidate
Brand Names
Azstarys, Focalin
Dexmethylphenidate
Brand Names
Azstarys, Focalin
Form: Tablet, Capsule
Method of administration: Oral
FDA approval date: November 30, 2001
Classification: Central Nervous System Stimulant
AZSTARYS is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older. AZSTARYS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older. ( 1 )
Showing 1-5 of 6
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances